SYNGENE INTERNATIONAL LIMITED

• Biocon plans to invest $150 million in capital expenditure over the next two years, with $100 million allocated to biologics expansion in Malaysia and $50 million to generics. • The biopharmaceutical company reported a 153% surge in Q4 net profit to Rs 344 crore, driven by strong growth in generics and steady progress in biosimilars. • Biocon is expanding its product portfolio with recent launches of lenalidomide and dasatinib in the US, liraglutide in the UK, and plans to launch bevacizumab and insulin aspart in the US market.

• Genflow Biosciences has received a £434,083 institutional investment to accelerate its 2025 programs, including a clinical trial testing SIRT6 gene therapy in aged dogs. • The company has commenced a randomized, controlled trial with 28 dogs aged 10+ years to evaluate the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline. • CEO Dr. Eric Leire has separately invested £500,000 in the company, calling it "a strong vote of confidence in our science" as Genflow advances research that could potentially benefit both veterinary and human medicine.

• Antibody-drug conjugates (ADCs) are gaining traction in APAC, marked by significant investments and collaborations, particularly from Chinese companies, signaling strong potential in targeted cancer therapies. • Cell and gene therapies (CGTs) are experiencing a surge in APAC, with China leading in CAR-T clinical trials and approvals, indicating a growing focus on innovative treatments for oncology and other diseases. • Artificial intelligence (AI) is becoming integral in APAC's pharmaceutical sector, enhancing drug discovery, clinical trials, and personalized medicine, with AI-designed drugs nearing regulatory approval. • The APAC region is solidifying its dominance in clinical trials, driven by a large patient population and regulatory reforms, particularly in oncology, attracting both local and global pharmaceutical firms.